Pancreatic Cancer | PanaSee blood test

PanaSee™ is a blood test that identifies people with an elevated risk of pancreatic cancer. Although pancreatic cancer has a high mortality rate, the incidence in the general population is too low to justify routine screening. PanaSee changes this. The incidence of pancreatic cancer in subjects with positive PanaSee test results is up to 100-fold higher than in people with negative PanaSee test results.

The PanaSee test measures levels of the metabolite PC-594 in the blood. If your PC-594 level is low (a positive PanaSee test), your risk of pancreatic cancer is high. A low PC-594 level doesn’t mean that you have pancreatic cancer – just that your
risk for pancreatic cancer is increased and you should seek further medical advice.

People with positive PanaSee results should speak to their physician about managing their risk. This could include medical imaging or further surveillance.

 
The PanaSee test is intended for use in risk assessment and monitoring; it is not a standalone diagnostic test, and is not a screening test for pancreatic cancer.
Stacks Image 10
PanaSee identifies increased risk by splitting the general population into two groups: one with a higher than average incidence of pancreatic cancer (red line) and one with a lower than average incidence (green line). The yellow line represents the current pancreatic cancer incidence by age in Canada. For any subject under age 65 who tests positive on PanaSee, the risk of pancreatic cancer is up to four times greater than the risk associated with having three first degree relatives diagnosed with the disease.

For comparison, the incidence of colorectal cancer is plotted (dotted grey line). The incidence of colorectal cancer (CRC) beginning at age 50 (in the absence of other risk factors) is considered high enough to warrant the costs and risks of performing colonoscopy on everyone age 50 or older. Since the incidence of pancreatic cancer among subjects with positive PanaSee test results is predicted to be at least 2.5 times higher than colon cancer in the general population (considered sufficient to warrant colonoscopy), assessing the population for pancreatic cancer risk with PanaSee warrants consideration.

Publications

- Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. BMC Cancer 2013, 13, 416.
- Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9. World J Gastroenterol. 2015 Jun 7; 21(21): 6604–6612.
- Serum metabolite profiling for the detection of pancreatic cancer. Results of a large independent validation study. Pancreas, August 11, 2016.